International Vaccine Institute strategic demand forecasting; and Sabin – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013-2015, with funding from Germany’s Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil’s Butantan Institute and Vietnam’s VaBiotech. After the 2016 licensure of Sanofi Pasteur’s Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to
South American Institute of Government in Health and the Directive and Consultative Councils. The Executive Board is responsible for administering ISAGS according to the goals, functions, policies, plans, programs and projects established and approved by the Directive Council. The Directive Council is one of ISAGS’s permanent units and carries out directive functions, guided by the priorities established at the South American Health Council. It is formed by delegates assigned by the Health Ministers of member countries and is responsible for defining institutional policies. The Consultative Council, responsible for producing recommendations regarding the planning, management, implementation and evaluation of ISAGS’s programs, is formed by: South American Institute of